Russ Johannesson said on LinkedIn that he stepped down from the CEO post at Glooko. He held the corner office for six-and-a-half years as Alvarez now takes over. Alvarez brings more than two decades of leadership experience in medical devices and biotechnology.
Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. The company’s recent endeavors include digital therapeutics and insulin delivery partnerships.
“On behalf of the board of directors, we are delighted to welcome Mike Alvarez as the new leader of Glooko,” said Simon Chong, Glooko board chair. “Mike brings significant industry expertise, proven leadership and commercial success across chronic condition management and population health, as well as experience with advanced data management technologies. We believe Mike is the right leader at a key inflection point for Glooko and look forward to working with him.”
Most recently, Alvarez served as CEO of Qardio, a leader in remote patient monitoring and technology solutions for chronic diseases. Prior to Qardio, Alvarez held leadership positions at Medtronic, St. Jude Medical (acquired by Abbott) and Sanofi.
“I am thrilled to join Glooko at this pivotal moment in its journey,” Alvarez said. “I look forward to continued commercial acceleration as we leverage real-world data to transform chronic condition management and improve enrollment and management in clinical trials through diverse and inclusive populations.”
Georgian led the company’s $100 million funding round. Health Catalyst Capital, Canaan and other investors and business partners participated. The company said the funds support its continued growth and product expansion.
